Kidney Week 2020 Reimagined: Call for Abstracts
ASN will accept submissions for research abstracts and clinical case reports electronically from April 15, 2020 through June 1, 2020 (2:00 p.m. EDT). ASN requires ASN User Logins and completed financial and other relationship DISCLOSURES FOR ALL AUTHORS. Please allow adequate time to gather this information by June 1, 2020. (The call for late-breaking clinical trials will open in July.)
Table of Contents
- New This Year
- General Guidelines
- Submission Information
- Assignment, Notification & Presentation
- Confidential Advanced Access
New This Year
ASN is committed to doing everything we can to help our members and the rest of the kidney community care for people with kidney diseases as well as adjust to this new reality resulting from the COVID-19 pandemic. With the cancelation of some nephrology meetings and the transition from live to virtual of other meetings, ASN has received requests for the society to accommodate abstracts that were accepted at other meetings in 2020 to be submitted for consideration at this year's Kidney Week.
For Kidney Week 2020, ASN has updated its standard embargo policy and will consider submissions of research abstracts and clinical case reports that were published and/or presented in 2020. During the submission process, the publication and/or meeting where the abstract or case report was released must be noted. This information will not impact ASN's decision on the abstract/case report acceptance.
New Coronavirus (COVID-19) Category: Kidney professionals across the globe have advanced care under extraordinary circumstances this year. They have simultaneously focused significant efforts studying the impact of COVID-19 on kidney health and diseases. Please submit your research and clinical cases pertaining to COVID-19 and related kidney health issues, including dialysis, acute kidney injury, and transplantation. This opportunity will also be available for the late-breaking clinical trial submissions.
- All types of nephrology-related research are eligible for submission and should address scientific questions, detail clinical observations, or contain preliminary scientific data.
- Abstracts are NOT eligible for consideration if the research has been published before January 1, 2020 and/or presented (oral or poster) at another meeting or press conference before January 1, 2020.
- Posting of un-refereed manuscripts to a community preprint server by authors will not be considered prior publication, provided that the following conditions are met:
- During submission, authors must acknowledge preprint server deposition.
- Versions of a manuscript that have been altered as a result of the peer review process may not be deposited;
- The preprint version cannot be indexed (e.g., in MEDLINE or PubMed).
- Upon ASN publication, authors are responsible for updating the archived preprint version with a link to the ASN Abstract Supplement PDF.
- The preprint server should meet NIH standards for interim research product repositories.
- Submission of multiple abstracts on a single study may result in the rejection of one or more abstracts.
- All research and studies in submitted abstracts must comply with the WMA Declaration of Helsinki, the Declaration of Istanbul on Organ Trafficking and Transplant Tourism, and the NIH Guide for the Care and Use of Laboratory Animals.
- Accepted abstracts may be assigned for oral presentation, assigned for poster presentation, and/or published in the ASN Abstract Supplement PDF.
- Important! If your research data are available by June 1, 2020, ASN strongly recommends that you submit your abstract during the regular call for abstracts, rather than holding it for the call for late-breaking clinical trials. The regular call for abstracts has more opportunities for oral presentations and posters than the call for late-breaking clinical trials.
Clinical Case Reports
- Case reports must include uniqueness of the case, clinical findings presented, outcomes documented, and "take-away" lessons (teaching points).
- There is a limit of 2 case report submissions per first author (presenting author).
- Case reports are NOT eligible for consideration if the case has been published before January 1, 2020 and/or presented (oral or poster) at another meeting before January 1, 2020.
- Accepted case reports may be assigned for poster presentation and/or published in the ASN Abstract Supplement PDF (generally not oral presentation).
- All research abstracts and clinical case reports ("abstracts") must be submitted electronically through the ASN abstract submission site by Monday, June 1, 2020, 2:00 p.m. EDT for consideration. (The call for informational posters has different dates of June 10 - July 1, 2020.)
- Submitter/Submitting Author: This individual serves as the secondary point of contact with ASN regarding the submission. The submitter is not required to be a contributing author (e.g., administrative assistant or student working with the authors) but must have an ASN User Login with current contact information for submission.
- Lead Author: This individual is the first author listed in the submission and has the primary responsibility for communications with ASN. This individual must have an ASN User Login with current contact information for submission.
- Click here if the lead author has an ASN User Login but forgot his/her password.
- Click here if the lead author needs to create an ASN User Login.
- This individual must have a current financial and other relationship disclosure affidavit on file with ASN. (Click here for the ASN Conflict of Interest and Disclosure Policy.)
- This individual is responsible for ensuring that all co-authors and company sponsors approve the submission, publication, and potential presentation.
- This individual will give the oral or poster presentation if the submission is accepted. The lead author should feel comfortable presenting and answering questions in English.
- Co-Authors: Each co-author must have an ASN User Login with current contact information and must have a current financial and other relationship disclosure affidavit on file with ASN. The co-authors will be listed in the order provided during submission.
- Authors and Contributors: With regard to authorship credit, ASN has adopted the criteria recommended by the International Committee of Medical Journal Editors (ICMJE) in the current update of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: "Authorship credit should be based on 1) substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; and 3) final approval of the version to be published. Authors should meet conditions 1, 2, and 3."
Note the full text of the ICMJE Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals. In addition, with regard to contributors, ASN has adopted the following statement of editorial policy from the Information for Authors of the Annals of Internal Medicine: "Medical writers and industry employees can be legitimate contributors, and their roles, affiliations, and potential conflicts of interest should be described when submitting manuscripts (Daskalopoulou, Jacobs). These writers should be acknowledged on the byline or in the Acknowledgments section in accord with the degree to which they contributed to the work reported in the manuscript. The editors consider failure to acknowledge these contributors ghostwriting, which is contrary to Annals' editorial policy."
- An abstract submission may contain a maximum of 2,500 characters, and the count includes characters and spaces in the following: Authors Names, Title, Body, Figure, and Table. Figure count is determined by image height but will not exceed 560 characters. Table count is 50 characters per row. Please note that Author Institutions do not count towards the character count.
- The abstract submission may be completed on the first visit to the submission site or may be saved and completed at a later time. An abstract may be submitted and paid for, then returned to draft, edited, and resubmitted for no additional fee before June 1, 2020 at 11:59 p.m. If the lead author does not receive an email confirmation within two business days of submission, please email email@example.com immediately. Lack of email confirmation indicates that ASN did not receive the submission.
- There is no limit to the number of research abstracts that an individual may submit. There is a limit of 2 clinical case reports per first author (presenting author). The $65 processing fee per submission is nonrefundable. The processing fee must be paid at the time of submission by credit card (American Express, MasterCard, or VISA).
- Upon abstract submission, the lead author and co-authors agree to all copyright transfer terms and the ASN embargo policy.
- Primary responsibility for compliance with any disclosure or nondisclosure requirements resides solely with researchers.
- Changes: It is important that the lead author checks the abstract data carefully before submission. Through June 1, 2020 at 2:00 p.m. EDT, submitted abstracts may be returned to draft, edited, and re-submitted. Between this date/time and June 12, 2020, for submitted abstracts needing minimal changes, the submitter or lead author can email firstname.lastname@example.org with the abstract number in the subject line and the ASN Abstract Change Form attached. After June 12, 2020, no changes will be allowed, including author updates. If accepted for presentation/publication, your abstract will be printed as it was submitted with any changes as of June 12, 2020. ASN has the authority to make standard copyediting changes (e.g., spelling errors, capitalizations, abbreviations).
- Withdrawals: The lead author can request abstract withdrawal through June 30, 2020 by emailing email@example.com. Please note the abstract number in the email subject line and the lead author's name in the email body. The $65 processing fee is nonrefundable. After June 30, withdrawal requests will be accepted on a case-by-case basis, but the abstract may still appear in meeting publications.
Assignment, Notification & Presentation
All abstract submissions are peer reviewed and authors' names and institutions are blinded to reviewers. ASN will email notifications to the lead authors and submitters of all abstract submissions by August 14, 2020. Accepted abstracts will be assigned to one of the following:
- "High-Impact Clinical Studies" Oral Session: This session for late-breaking clinical trials will be held on Friday, October 23, 2:00-4:00 p.m. Each abstract presentation will be followed by audience questions, facilitated by the session moderator(s).
- Oral Abstract Sessions: Oral Abstract Sessions will be held on Thursday, October 22, Friday, October 23, and Saturday, October 24 at 4:30-6:30 p.m. Each abstract presentation is allotted eight minutes followed by an additional four minutes of audience questions, facilitated by the session moderator(s). Abstracts accepted for oral presentations will be included in the ASN Abstract Supplement PDF, which will be posted online by October 9, 2020.
- Poster Presentations: Poster presentations will be available for viewing on Thursday, October 22, Friday, October 23, and Saturday, October 24 at 9:30 a.m. - 4:30 p.m. in the exhibit hall. If accepted for poster presentation, the lead author or a co-author must be available at the poster board at 10:00 a.m. - 12:00 p.m. for presentation and discussion. Abstracts accepted for poster presentations will be included in the ASN Abstract Supplement PDF, which will be posted online by October 9, 2020.
- Publication Only: Some abstracts will be included in the ASN Abstract Supplement but not presented during Kidney Week. To request removal from the Abstract Supplement, the lead author must check the box during the submission process that states "Please do not include my abstract in the ASN Abstract Supplement if my abstract is not selected for an oral or poster presentation." The ASN Abstract Supplement PDF will be posted online by October 9, 2020.
It is the responsibility of the lead authors to share the notifications with their co-authors. If you are a lead author and have not received your notification by August 14, 2020, please email firstname.lastname@example.org and note the abstract number in the email subject line and the lead author's name in the email body.
The presenting authors of abstracts accepted for oral or poster presentations must register for the Annual Meeting (fees apply) and make their own housing reservations. Please note that early registration closes on August 12, 2020.
Confidential Advanced Access
All abstracts submitted in connection with Kidney Week are disclosed to ASN's peer review committee, employees, and contractors as necessary. Although ASN and its employees or contractors cannot guarantee the confidentiality of submitted abstracts, every effort will be made to ensure confidentiality of submitted material.